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Abstract
Osteoarthritis (OA) is the most prevalent joint disease and a common cause of 
joint pain, functional loss, and disability. In addition to macroscopic features, such 
as cartilage degradation with subchondral bone remodeling, hypertrophy of the 
joint capsule, and osteophytes formation, several cellular and molecular alterations 
are present in OA, which lead to a chronic low-grade inflammation. Inflammatory 
mediators observed in OA joints are thought to be the downstream effectors of the 
pathogenesis of the disease. Although cytokines are among the most extensively 
studied mediators of inflammation, such as IL-1β and TNF, there has been an 
increase in studies showing the contribution of chemokines and adipokines in OA 
progression. This fact is supported by recent progress, which has considerably 
improved knowledge of the factors involved in the development of OA and the 
mechanisms responsible for its progression. Therefore, the aim of this chapter is to 
discuss the involvement of the inflammatory response in OA maintenance, focusing 
on the main inflammatory markers observed in studies with OA.
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1. Introduction
Osteoarthritis (OA) is a common disease that can affect joints from any part of 
the body, and it represents a major cause of disability and joint pain worldwide [1, 2].  
OA most commonly affects the knee, hip, and shoulder, and it was estimated that 
more than 25 million people in the USA were affected by some form of OA in the last 
decade [3]. In addition, OA presents a high susceptibility to affect female gender, 
elderly people, and obese individuals [4].
The progression of OA leads to cartilage degradation with subchondral bone 
remodeling, hypertrophy of the joint capsule, and osteophytes formation, causing 
pain [1, 5, 6]. Although the development of OA is considered a heterogeneous pro-
cess, which comprises a number of genetic and environmental causes, the presence 
of local causes, such as trauma and hypermobility of the joint, may worsen OA [2, 7].
The accurate identification of osteoarthritic features has been studied in order to 
radiographically grade the stages of OA. The Kellgren-Lawrence classification is the 
most widely used, especially in clinical researches. This classification evaluates the 
appearance of osteophytes and cysts, joint space loss, and sclerosis, and it grades 
the severity from 0 to 5 points. The radiological features found in OA joints were 
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graded as follows: (1) formation of osteophytes on joint margins or on tibia spines 
for knee OA; (2) periarticular ossicles in relation to distal and proximal interpha-
langeal joints; (3) narrowing of joint cartilage and sclerosis of subchondral bone; 
(4) pseudocystic areas with sclerotic walls in the subchondral bone; and (5) altered 
shape of the bone ends [8]. Some of these criteria were adopted by the World Health 
Organization (WHO) as the standard for studies on OA.
Current options for the treatment of OA focus on reducing pain (non-steroidal 
anti-inflammatory drugs—NSAIDs) and joint viscosupplementation (intra-
articular injections of hyaluronic acid) [1]. Besides presenting a short-term effect, 
the chronic use of some of these medications, especially NSAIDs, may cause serious 
adverse events, including toxicity and risk of thromboembolism [9, 10]. In severe 
cases, surgical procedures, mostly joint replacement, are suggested [1]. Novel 
alternative therapies, called orthobiologics, have emerged from the need of tissue 
regeneration. Clinical trials using orthobiologics, which comprise platelet-rich 
plasma (PRP), bone marrow aspirate concentrate (BMAC), fat graft (Biofat), and 
expanded mesenchymal stem cells, have shown promising results for the treatments 
of OA from any origin [11–14].
Moreover, monoclonal antibody (mAb) therapy represents one of the alterna-
tive treatments that aim to control inflammation and slow structural progression 
[15]. This approach focuses on blocking specific molecules responsible for the 
maintenance of OA. Preclinical studies with ADAMTS mAbs reported a significant 
decrease in histological scores after 3 months of treatment [16]. Adalimumab is an 
anti-TNF-α therapy used in diverse immune-mediated diseases, and it presents a 
protective role for OA as it reduces the severity of the cartilage lesion and improves 
the structure of subchondral bone [17]. Since IL-1 family may induces the produc-
tion of metalloproteinases (MMP), it has also become a target for mAb therapy, 
and, in a randomized controlled trial with patients who presented knee OA, it was 
reported great improvement on pain relief [18].
In addition to macroscopic features, several cellular and molecular alterations 
are present in OA, such as catabolism and anabolism events; hypertrophy and, 
consequently, death of chondrocytes; and impaired autophagy process [19]. Also, a 
chronic low-grade inflammation interplayed with immune system has been consid-
ered to present a crucial role in the maintenance of OA [1]. This fact is supported 
by recent progress, which has considerably improved the knowledge regarding 
factors involved in the OA development and the mechanisms responsible for its 
progression.
2. Osteoarthritis and immune response
The inflammation observed in OA is believed to involve innate immune response 
prior to a mild degree of adaptive immunity [20]. During tissue damage, a group 
of endogenous molecules, called damage-associated molecular pattern (DAMP), 
signals the immune cells to induce a protective response against the tissue, causing 
tissue repair. However, a prolonged signaling of DAMP to immune cells leads to an 
exacerbated cytokine release, which can be destructive to the tissue [21, 22].
Innate immune cells activated by DAMP include macrophages and mast cells, 
which have shown to present (displayed or demonstrated) a key role in the patho-
genesis of OA. Mast cells are considered regulators of vascular permeability, and 
they may play a crucial role in OA joint inflammation as they facilitate leukocyte 
infiltration [23].
Macrophages exhibit a functional plasticity based on the environment in which 
they are located or present [22]. However, their chronic activation can lead to the 
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production of proinflammatory cytokines, which worsen the osteoarthritic joints 
[24]. In vitro studies of human OA synovium-derived cells showed that macrophage 
depletion results in diminishing of inflammatory response by decrease of proteo-
lytic enzyme expression, such as metalloproteinases (MMP) This fact is supported 
by in vitro studies with cell culture suspension of human OA synovium, which 
reported that, after macrophage depletion, there was a decrease in the production 
of inflammatory response by less activity of proteolytic enzymes, such as metal-
loproteinases (MMP) [25]. Although macrophages may also present a protective 
role, as they are known to secrete transforming growth factor β (TGF-β), which 
would enhance cartilage repair, intra-articular injection of TGF-β in mice knee led 
to osteophyte formation and fibrosis [26].
In addition, natural killer (NK) infiltrates are commonly found in synovial 
tissue from patients who underwent joint replacement surgeries, and a subset of NK 
cells (CD56bright) was found to be greatly expanded in patients with inflammatory 
arthritis who have not undergone joint replacement surgeries. However, the effect 
of these cells on the development of OA has not been elucidated yet [27–29]. NK 
cells secrete protease enzymes called granzyme type A and B, which correlate to 
cytolytic potency. Granzymes can be released during degranulation of cytotoxic 
cells and, when delivered intracellularly to the target cells, they induce apoptosis. 
Granzyme A also stimulates the production of tumor necrosis factor (TNF-α), IL-6, 
and IL-8, while granzyme B may intensify the degradation of extracellular matrix 
[30, 31]. Tak et al. identified both types of granzymes in synovia from OA and 
rheumatoid arthritis. However, another study later showed that NK cells within OA 
synovia were granzyme negative with potential to produce the interferon-γ (IFN-γ) 
when expanded with IL-2 and stimulated with cytokines known to trigger IFN-γ 
production in blood NK cells, such as IL-12 and IL-18 [27, 32].
The presence of IFN-γ has a role in the bone resorption and consequently in the 
osteoclastogenesis process, but the studies have shown controversial results in this 
regard: in vitro evidence reported that IFN-γ, via TRANCE pathway, strongly sup-
presses osteoclastogenesis in culture of mononuclear phagocyte cells, which are the 
osteoclast precursors [33], whereas in culture of peripheral blood it may enhance 
osteoclast production as IFN-γ increases superoxide generation by neutrophils [34]. 
In addition, experimental studies in which IFN-γ receptor was silenced suggested a 
more rapid onset of collagen-induced arthritis [35]. Although IFN-γ plays a key role 
in angiogenesis, there is no evidence that this cytokine is able to promote angiogen-
esis in OA.
Proteins from complement system have been found to play a role in OA, especially 
in early stages, as they were upregulated in both synovial membrane and fluid [23, 36]. 
Additionally, the deposition of the membrane attack complex (MAC, C5b-9) is 
correlated with the presence of inflammation on histology of synovial membrane, 
and it was present in chondrocytes in late OA [36]. MAC can lead to chondrocyte 
destruction as it stimulates catabolic events through the increase of leukocytes and, 
consequently, the production of MMP [23]. Also in the studies with experimental 
knockout models for C5 and C6, the joint damages were attenuated [36].
Cellular infiltrates from adaptive immune response have also been observed in 
synovial fluid from OA joints. Although the main cell type present in this infiltrate 
is CD3+ T cells, both CD4+ and CD8+ cells have also been found in OA [37]. Th1 
cells, and consequently their secretory cytokines, such as IL-2 and INF-γ, appear 
to be expressed five times greater than Th2 in most of OA patients [37]. Based on 
lymphocyte aggregates, there is a suggestion of an active cell-mediated immune 
response since T-cells in lymphocytic aggregates in OA synovium were shown to 
bear early (CD69), intermediate (CD25 and CD38), and late (CD45RO) activation 
markers [38].
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3. Inflammatory markers in osteoarthritis
3.1 Cytokines
Inflammatory mediators observed in OA joints are thought to be the downstream 
effectors of the pathogenesis of the disease. Cytokines are among the most exten-
sively studied mediators of inflammation. Several cytokines have been reported to 
play a role in the progression of OA, such as TNF, IL-1β, IL-6, IL-15, IL-17, IL-18, 
IL-4, and IL-10. Although their precise mechanism of action has not been completely 
elucidated yet, it has been proposed that their presence influences cartilage homeo-
stasis as they induce catabolic events as well as inhibit anabolic processes [21, 39, 40].
3.1.1 IL-1β and TNF
Interleukin (IL)-1β and tumor necrosis factor (TNF) are considered the major 
mediators in the pathophysiology of OA. They both are secreted not only by immune 
cells, especially mononuclear cells, but also by chondrocytes and osteoblasts. In OA 
joints, these cytokines are increased in both synovial fluid and membrane. They are 
known to drive the inflammatory cascade, and their increased expression induces 
catabolic events as they enhance MMP [39]. IL-1β and TNF downregulate the 
synthesis of major extracellular matrix (ECM) components by inhibiting anabolic 
activities of chondrocytes [40] and reducing type II collagen production [41].
IL-1β is activated through the binding of its specific receptor type I (IL-1RI). 
Overexpression of IL-1RI in cartilage proximal to the macroscopic injury in OA 
joints resulting in increased binding of IL-1β was observed [42]. IL-1β has also been 
reported to be responsible for the catabolic events present in OA: its expression 
combined with TNF induces the production of MMP-1, -3, and -13 and stimulates 
the production of aggrecanases (ADAMTS)-4 and -5 in human and bovine chon-
drocytes [43, 44]. TNF receptor type I (TNFRI) is overexpressed in OA chondro-
cytes [45]. High levels of TNF-α in cartilage explants seem to inhibit the synthesis of 
proteoglycan and stimulate resorption [40].
In OA joint, IL-1β and TNF amplify the arthritic condition by inducing the pro-
duction of proinflammatory cytokines, such as IL-6, IL-8, and monocyte chemoat-
tractant protein 1. In addition, chondrocytes treated with IL-1β and TNF increase 
the production of nitric oxide (NO), cyclooxygenase 2 (COX-2), and prostaglandin 
E2 (PGE2), which contribute to articular inflammation and cartilage destruction 
as they enhance MMP activity, inhibit the production of anabolic products such as 
collagen and proteoglycan, and induce chondrocyte apoptosis [39].
The catabolic events observed (the catabolic events that occur due to the pres-
ence of…) in the presence of IL-1β and TNF are mediated through the activation of 
signaling pathways, including nuclear factor-κB (NF-κB) signaling. NF-κB pathway 
induces the expression of the genes related to the inflammatory mediators cited 
above and also contributes to the induction of MMP-1 and -13 and ADAMTS-4 
[46]. However, some signaling pathways are involved in the downregulation of the 
IL-1β and TNF effects in OA, such as peroxisome proliferator-activated receptor-γ 
(PPAR-γ). The activation of PPAR-γ seems to reduce the progression of cartilage 
lesion in experimental models of OA as it assists the downregulation of inflamma-
tory and catabolic responses mediated by IL-1β and TNF [47, 48].
3.1.2 IL-6
IL-6 is a proinflammatory cytokine, whose signaling pathway involves the 
activation of receptors, such as membrane-bound IL-6 receptor (IL6R), soluble 
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IL-6R (sIL-6R), and gp130, followed by the activation of STAT1 and STAT3 path-
ways [39]. In physiological conditions, the production of IL-6 by chondrocytes is 
considerably low. However, the exact mechanism of IL-6 action in OA is unknown, 
but its production can be stimulated by the number of cytokines and growth factors 
present in OA, including IL-1β, TGF-β, and PGE2 [25, 49].
Increased levels of IL-6 in synovial fluid and serum have been correlated with 
the severity of lesions in X-ray imaging [50]. In vitro studies have shown that 
IL-6, in combination with IL-1β and TNF, upregulates the production of MMP-1 
and -13 in human and bovine chondrocytes and induces proteoglycan and type II 
collagen degradation [51, 52]. The effect of IL-6 in studies with animal models has 
shown uncertain results. IL-6 knockout mice revealed more advanced degenerative 
changes compared to wild-type animals [53]. However, when IL-6 was injected in 
the joint cavity of IL-6-deficient mice, the reduction in the loss of proteoglycans in 
the acute phase of inflammation was observed [54].
One of the most considered active components in OA is the change in subchon-
dral bone tissue, and IL-6 has been a critical mediator in this regard. Its effect, 
together with IL-1β and TNF, is based on promoting osteoclast formation and, 
consequently, bone resorption [55]. In response to IL-6, osteoblasts stimulate the 
production of receptor activator of NF-κB ligand, IL-1β, and PGE2, which activate 
osteoclasts [56]. In addition, osteoblasts activated by these cytokines produce 
MMPs, which adversely affect the surrounding cartilage [57].
3.1.3 IL-15
Despite a better documented involvement in rheumatoid arthritis [58], the knowl-
edge regarding IL-15 and its action in OA is still poor. It acts based on the stimulation 
and proliferation of T cells and NK cells, and it may also induce the production of MMP 
[59]. IL-15 levels are elevated in synovial fluid in early stages of OA, and this concen-
tration correlates with pain and severity of lesions seen on X-ray imaging [60, 61].
3.1.4 IL-17
Due to its inflammatory effects, IL-17 family has been implied to play a role 
in OA [62]. IL-17 is mainly stimulated by CD4+ T cells and mast cells, which are 
present in the cellular infiltrates observed in OA joints [63]. Within the joints, IL-17 
primarily targets chondrocytes and fibroblast-like synoviocytes, which express 
IL-17 receptor (IL-17R) on their surface [64]. It was reported that IL-17 is able to 
inhibit proteoglycan synthesis by chondrocytes and increase the production of 
MMPs [65]. Also, high levels of IL-17 in both serum and synovial fluid were cor-
related with radiographic lesions in OA [66].
The genetic correlation between IL-17 and OA was suggested: a polymorphism 
in the gene IL-17A G-197A could be associated with the susceptibility to the devel-
opment of OA [67]. In addition, IL-17 is produced by a specific T cell lineage called 
T helper 17, and it is able to cause hypertrophy of synovial membrane as its presence 
influences the secretion of vascular endothelial growth factor (VEGF), which leads 
to excessive blood vessel formation [68]. It can also indirectly affect cartilage by 
inducing the production of cytokines responsible for tissue degradation, such as 
IL-1β, TNF, IL-6, NO, and PGE2 [64].
3.1.5 IL-18
The active form of IL-18 results from the activation of caspase-1, which has been 
reported to be elevated in articular cartilage and synovium of OA, leading to great 
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promotion of IL-18 and IL-1β. The production of IL-18 in joints is mainly deter-
mined by chondrocytes, osteoblasts, and macrophages [69]. IL-18 affects cartilage 
by upregulating the production of IL-18Rα on chondrocyte surface and stimulates 
excessive production of MMP-1, -3, and -13 [70]. Also, IL-18 negatively influences 
the production of proteoglycans, aggrecan, and type II collagen and may cause 
morphological changes typically observed in apoptotic processes [71, 72].
The increased concentration of IL-18 observed in synovial fluid, synovium, 
cartilage, and even blood serum from patients with OA has been correlated with the 
severity of lesions seen in radiographic imaging [73]. Also, studies have correlated 
the development of OA and lumbar disc degeneration with polymorphisms in the 
gene encoding IL-18 and its receptor (IL-18R) [74, 75].
3.1.6 IL-4
Anti-inflammatory cytokines also present a role in the maintenance of OA. IL-4 
is associated with chondroprotective effects as it is shown to reduce MMP production 
and, consequently, inhibit the degradation of proteoglycans in the articular cartilage 
[76]. However, chondrocytes from OA joints have shown a decreased susceptibil-
ity to this IL-4 protective effect, leaving the cartilage unprotected, quickening the 
degeneration via the action of the proinflammatory cytokines cited above [77]. In 
addition, a polymorphism in the gene encoding IL-4 and its main receptor (IL-4Rα) 
could predetermine the development of OA in hand and knee joints [78, 79]. It was 
also further reported that, when compared with healthy patients, OA patients pres-
ent an elevated level of soluble IL-4Rα (sIL-4Rα) [80].
The activation of IL-4 depends on intracellular signal transduction by gradual 
phosphorylation of IL-4Rα, which leads to the expression of several proinflamma-
tory genes [81]. IL-4 production is mainly determined by T cells, especially Th2, 
which are present in the cellular infiltrates observed in OA [37]. It was reported that 
IL-4 alone or in combination with IL-10 is able to reduce the production of diverse 
proinflammatory mediators, such as IL-1β, TNF-α receptors, IL-6, PGE2, and 
COX-2 [82–84].
3.1.7 IL-10
Due to its anti-inflammatory features, IL-10 is another cytokine that presents 
chondroprotective effects, and it is linked to the release of IFN [62]. In vitro studies 
have shown increased proteoglycan and type II collagen syntheses after the admin-
istration of IL-10 in chondrocytes [62]. The protective effects that IL-10 exhibits are 
likely due to a stimulation of the synthesis of IL-1β antagonist and a tissue inhibi-
tion of MMP-1 (TIMP-1) [85]. Also, IL-10, as well as IL-4, reduces apoptotic events 
in chondrocytes and production of MMP [86, 87].
IL-10 induces the expression of bone morphogenetic protein-2 and -6 (BMP2 
and BMP6), which are related to chondrogenesis as they belong to TGF-β family 
[88]. Together with BMP production, IL-10 activates signaling pathways, such as 
NKX-3.2/SOX9, that induce the differentiation of mesenchymal stem cells into 
chondrocytes [89]. Also, by reducing the expression of TNF-α receptors, IL-10 is 
able to attenuate the effect of TNF-α on synovial fibroblasts. A decrease in COX-2 
production was also noted in the same study [90].
The secretion of IL-10 can be influenced by physical exercises. Patients with 
and without OA had synovial fluid and periarticular tissue harvested from their 
knee before, during, and after they underwent exercise practice for 3 hours. A 
significant increase in IL-10 levels was observed in these patients after the exercise. 
Although it is not clear what exact mechanism led to this result, this observation is 
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likely attributed to an increase in intra-articular pressure and subsequent effects on 
cellular secretion [91, 92].
3.2 Chemokines
Chemokines comprise small proteins that act as chemoattractants to assist cells 
to migrate to injured tissue. Diverse chemokines have gained attention in the devel-
opment of OA. Some of them including their receptors, such as IL-8, CCL5, CCL19, 
CCR1, CCR2, CCR3, and CCR5, may induce the production of MMP-3 by chondro-
cytes and increase the breakdown of cartilage matrix components, which trigger 
the onset of OA [60, 93]. However, some chemokines might present a protective 
role in OA, such as stromal cell-derived factor-1 (also called CXCL12), whose main 
function is to recruit mesenchymal stem cells to the injured area in order to promote 
tissue repair [94].
Several chemokines were reported to be overexpressed in OA, such as IL-8/
CXCL-8, GROα/CXCL-1, MCP-1/CCL-2, RANTES/CCL-5, MIP-1α/CCL-3, and 
MIP-1β/CCL-4. Some of these chemokines are stimulated by IL-1β, which is 
upregulated in OA, and they induce MMP production upon binding to their ligands, 
causing tissue degradation [93]. Levels of INF-γ-inducible protein 10 (IP-10), 
also called as CXCL-10, in plasma and synovial fluid have been correlated with 
radiographic knee OA. CX3CL1, a serum fractalkine, has also been reported to be 
significantly elevated in severe knee OA in a study that compared OA patients with 
healthy patients [95].
To support the role of macrophage in the inflammatory response observed 
in OA, MCP-1, also known as chemokine ligand-2 (CCL2), has been reported to 
recruit macrophages into adipose tissue and atherosclerotic lesions [96]. Also, 
MCP-1 levels in both serum and synovial fluid has been associated with self-
reported pain and disability in patients who present knee OA [97]. In addition, it 
was observed that, in severe knee OA, the levels of macrophage-derived chemokine 
(MDC) and IP-10 in synovial fluid were elevated, while eotaxin levels, an eosino-
phil chemotactic protein, were lower when compared with healthy patients [98].
3.3 Adipokines
Adipokines have been associated with the incidence and severity of OA [99]. In 
vitro studies reported that the presence of adipokines, such as leptin, adiponectin, 
visfatin, and resistin, increases the production of inflammatory mediators and also 
induces chondrolysis [99]. Although the exact mechanism of how these cytokines 
derived from adipose tissue act on arthritic joints has not yet been elucidated, research-
ers have studied the role of fat pad as a local inflammation mediator in OA, particu-
larly in knee OA due to the infrapatellar fat pad, which has proven to be infiltrated 
with macrophages, lymphocytes, and granulocytes [100]. These findings support 
the thought that obesity supports the development of OA more through biochemical 
pathways rather than biomechanical overload risks on a weight-bearing joint.
3.4 Lipid mediators
The COX-2 enzyme is responsible for the production of lipid mediators, includ-
ing PGE2 and leukotrienes, and it is also upregulated in OA joints. In addition, the 
overexpression of COX-2 in OA has been associated with the increased production 
of IL-1β, TNF, and IL-6 via toll-like receptor-4 (TLR-4) [101]. Besides assisting the 
production of MMPs and other functions already cited above, PGE2 is also involved 
in apoptosis and structural changes that characterize arthritic disease [102].
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Leukotrienes have also been investigated for their role in OA. These mediators 
are converted from arachidonic acid, which also produces PGE2 via the activity of 
the enzyme phospholipase A2 [21]. Leukotrienes, mainly leukotriene B4 (LTB4), are 
present, to a lesser extent, in OA synovium, bone, and cartilage. Also, LTB4 has been 
reported to stimulate the production of IL-1β and TNF in arthritic synovium [103].
4. Conclusions
The cumulative evidences over the years have shown that increased expression 
of proinflammatory cytokines, in particular IL-1β, TNF, and IL-6, in cartilage as 
well as synovial fluid and membrane, has played a key role in the pathogenesis of 
OA. Inflammatory processes linked with immune responses have characterized OA 
as a complex disease and not as a simple age-related cartilage degeneration as it is 
thought to be. The understanding of individual roles of inflammatory mediators 
and their compounds is of utmost importance to target new therapies for OA, since 
the current options are elusive and may be noneffective, invasive, or even capable of 
presenting serious side effects. Due to advancements in molecular tools, the overall 
aim would be to dissect the role of each cytokine in the pathophysiology of OA and, 
together with drug delivery systems, to develop specific anticytokine therapy, given 
that inflammatory responses contribute substantially to OA maintenance.
Conflict of interest
The authors have no conflict of interest to declare.
Author details
José Fábio dos Santos Duarte Lana* and Bruno Lima Rodrigues
Institute of Bone and Cartilage, Indaiatuba, Sao Paulo, Brazil
*Address all correspondence to: josefabiolana@gmail.com
9Osteoarthritis as a Chronic Inflammatory Disease: A Review of the Inflammatory Markers
DOI: http://dx.doi.org/10.5772/intechopen.82565
References
[1] Robinson WH, Lepus CM, Wang 
Q, Raghu H, Mao R, Lindstrom TM, 
et al. Low-grade inflammation as a 
key mediator of the pathogenesis 
of osteoarthritis. Nature Reviews 
Rheumatology. 2016;12(10):580-592
[2] Jonsson H, Olafsdottir S, 
Sigurdardottir S, Aspelund T, 
Eiriksdottir G, Sigurdsson S, et al. 
Incidence and prevalence of total joint 
replacements due to osteoarthritis in 
the elderly: Risk factors and factors 
associated with late life prevalence 
in the AGES-Reykjavik study. 
BMC Musculoskeletal Disorders. 
2016;17(1):1-9
[3] Helmick CG, Felson DT, Lawrence 
RC, Gabriel S, Hirsch R, Kwoh CK, et al. 
Estimates of the prevalence of arthritis 
and other rheumatic conditions in the 
United States. Part I. Arthritis and 
Rheumatism. 2008;58(1):15-25
[4] Blagojevic M, Jinks C, Jeffery A, 
Jordan KP. Risk factors for onset of 
osteoarthritis of the knee in older 
adults: A systematic review and meta-
analysis. Osteoarthritis and Cartilage. 
2010;18(1):24-33
[5] Sellam J, Berenbaum F. The role 
of synovitis in pathophysiology and 
clinical symptoms of osteoarthritis. 
Nature Reviews Rheumatology. 
2010;6(11):625-635
[6] Mapp PI, Walsh DA, Bowyer 
J, Maciewicz RA. Effects of a 
metalloproteinase inhibitor on 
osteochondral angiogenesis, 
chondropathy and pain behavior in a rat 
model of osteoarthritis. Osteoarthritis 
and Cartilage. 2010;18(4):593-600
[7] Sharma L, Cooke TD, Guermazi 
A, Roemer FW, Nevitt MC. Valgus 
malalignment is a risk factor for 
lateral knee osteoarthritis incidence 
and progression: Findings from the 
multicenter osteoarthritis study and 
the osteoarthritis initiative. Arthithis 
Rheumatism. 2014;65(2):355-362
[8] Kellgren JH, Lawrence JS. 
Radiological assessment of osteo-
arthrosis. Annals of the Rheumatic 
Diseases. 1957;16(4):494-502
[9] Solomon DH, Husni ME, Libby PA, 
Yeomans ND, Lincoff AM, Lüscher TF, 
et al. The risk of major NSAID toxicity 
with celecoxib, ibuprofen, or naproxen: 
A secondary analysis of the PRECISION 
trial. The American Journal of Medicine. 
2017;130(12):1415-1422.e4
[10] Lee T, Lu N, Felson DT, Choi HK, 
Dalal DS, Zhang Y, et al. Use of non-
steroidal anti-inflammatory drugs 
correlates with the risk of venous 
thromboembolism in knee osteoarthritis 
patients: a UK population-based 
case-control study. Rheumatology, 
2016;55(6):1099-1105
[11] Lana J, Weglein A, Sampson S, 
Vicente F, Huber S, Souza C, et al. 
Randomized controlled trial comparing 
hyaluronic acid, platelet-rich plasma 
and the combination of both in the 
treatment of mild and moderate 
osteoarthritis of the knee. Journal of 
Stem Cells and Regenerative Medicine. 
2016;12(2):69-78
[12] Dallari D, Stagni C, Rani N, 
Sabbioni G, Pelotti P, Torricelli P, 
et al. Ultrasound-guided injection of 
platelet-rich plasma and hyaluronic 
acid, separately and in combination, 
for hip osteoarthritis. The American 
Journal of Sports Medicine. 
2016;44(3):664-671
[13] Centeno CJ, Al-Sayegh H, Bashir 
J, Goodyear SH, D Freeman M. A 
prospective multi-site registry study of 
a specific protocol of autologous bone 
marrow concentrate for the treatment 
Osteoarthritis Biomarkers and Treatments
10
of shoulder rotator cuff tears and 
osteoarthritis. Journal of Pain Research. 
2015;8:269-276
[14] Jo C, Lee Y, Shin W, Kim H, 
Chai J, Jeong E, et al. Intra-Articular 
Injection of Mesenchymal Stem Cells 
for the Treatment of Osteoarthritis of 
the of the Knee: A Proof-of-Concept 
Clinical Trial CHRIS. Stem cells. 
2014;32(5):1254-1266
[15] Zheng S, Hunter DJ, Xu J, Ding 
C. Monoclonal antibodies for the 
treatment of osteoarthritis. Expert 
Opinion on Biological Therapy. 
2016;16(12):1529-1540
[16] Chiusaroli R, Visentini M, 
Galimberti C, Casseler C, Mennuni 
L, Covaceuszach S, et al. Targeting of 
ADAMTS5’s ancillary domain with the 
recombinant mAb CRB0017 ameliorates 
disease progression in a spontaneous 
murine model of osteoarthritis. 
Osteoarthritis and Cartilage [Internet]. 
2013;21(11):1807-1810. DOI: 10.1016/j.
joca.2013.08.015
[17] Ma CH, Lv Q, Yu YX, Zhang Y, Kong 
D, Niu KR, et al. Protective effects of 
tumor necrosis factor—A blockade 
by adalimumab on articular cartilage 
and subchondral bone in a rat model 
of osteoarthritis. Brazilian Journal 
of Medical and Biological Research. 
2015;48:863-870
[18] Cohen SB, Proudman S, Kivitz AJ, 
Burch FX, Donohue JP, Burstein D, et al. 
A randomized, double-blind study of 
AMG 108 (a fully human monoclonal 
antibody to IL-1R1) in patients with 
osteoarthritis of the knee. Arthritis 
Research & Therapy [Internet]. 
2011;13(4):R125. Available from: http://
arthritis-research.biomedcentral.com/
articles/10.1186/ar3430
[19] Loeser RF, Goldring SR, Scanzello 
CR, Goldring MB. Osteoarthritis: A 
disease of the joint as an organ. Arthritis 
and Rheumatism. 2013;64(6):1697-1707
[20] Haseeb A, Haqqi TM. 
Immunopathogenesis of osteoarthritis. 
Clinical Immunology. 2009;6(3):247-253
[21] Sokolove J, Lepus CM. Role of 
inflammation in the pathogenesis of 
osteoarthritis: Latest findings and 
interpretations. Therapeutic Advances in 
Musculoskeletal Disease. 2013;5(2):77-94
[22] Orlowsky EW, Kraus VB. The role 
of innate immunity in osteoarthritis: 
When our first line of defense goes on 
the offensive. The Journal of  
Rheumatology. 2015;42(3):363-371
[23] Kandahari AM, Yang X, Dighe 
AS, Pan D, Cui Q. Recognition of 
immune response for the early diagnosis 
and treatment of osteoarthritis. 
Journal of Immunology Reseach. 
2015;2015(192415):1-13
[24] Pessler F, Dai L, Diaz-Torne C, 
Gomez-Vaquero C, Paessler ME, 
Zheng DH, et al. The synovitis of 
“non-inflammatory” orthopaedic 
arthropathies: A quantitative 
histological and immunohistochemical 
analysis. Annals of the Rheumatic 
Diseases. 2008;67(8):1184-1187
[25] Bondeson J, Wainwright SD, 
Lauder S, Amos N, Hughes CE. The 
role of synovial macrophages and 
macrophage-produced cytokines 
in driving aggrecanases, matrix 
metalloproteinases, and other 
destructive and inflammatory responses 
in osteoarthritis. Arthritis Research & 
Therapy. 2006;8(6):1-12
[26] Van Lent PLEM, Blom AB, Van 
Der Kraan P, Holthuysen AEM, 
Vitters E, Van Rooijen N, et al. Crucial 
role of synovial lining macrophages 
in the promotion of transforming 
growth factor?—Mediated osteophyte 
formation. Arthritis and Rheumatism. 
2004;50(1):103-111
[27] Huss RS, Huddleston JI, Goodman 
SB, Butcher EC, Zabel BA. Synovial 
tissue-infiltrating natural killer cells 
11
Osteoarthritis as a Chronic Inflammatory Disease: A Review of the Inflammatory Markers
DOI: http://dx.doi.org/10.5772/intechopen.82565
in osteoarthritis and peri-prosthetic 
inflammation. Arthritis and 
Rheumatism. 2011;62(12):3799-3805
[28] Xiaoqiang E, Yang C, Hongxue 
M, Yuebin Q, Guangye D, Jun X, Bi 
Z. Dendritic cells of synovium in 
experimental model of osteoarthritis 
of rabbits. Cellular Physiology and 
Biochemistry. 2012;30(1):23-32
[29] Dalbeth N, Callan MFC. 
A subset of natural killer cells is 
greatly expanded within inflamed 
joints. Arthritis and Rheumatism. 
2002;46(7):1763-1772
[30] Sower LE, Klimpel GR, Hanna 
W, Froelich CJ. Extracellular 
activities of human granzymes. 
Cellular Immunology [Internet]. 
1996;171(1):159-163. Available from: 
http://www.ncbi.nlm.nih.gov/
pubmed/8660852
[31] Froelich CJ, Dixit VM, Yang 
X. Lymphocyte granule-mediated 
apoptosis: Matters of viral mimicry and 
deadly proteases. Immunology Today. 
1998;19(1):30-36
[32] Tak PP, Spaeny-Dekking L, Kraan 
MC, Breedveld FC, Froelich CJ, Hack 
CE. The levels of soluble granzyme 
A and B are elevated in plasma 
and synovial fluid of patients with 
rheumatoid arthritis (RA). Clinical 
and Experimental Immunology. 
1999;116:366-370
[33] Fox SW, Chambers TJ. Interferon-γ 
directly inhibits TRANCE-induced 
osteoclastogenesis. Biochemical and 
Biophysical Research Communications. 
2000;276(3):868-872
[34] Madyastha PR, Yang S, Ries WL,  
Key LL. IFN-γ enhances osteoclast 
generation in cultures of peripheral 
blood from Osteopetrotic patients 
and normalizes superoxide 
production. Journal of Interferon 
& Cytokine Research [Internet]. 
2000;20(7):645-652. Available from: 
http://www.liebertonline.com/doi/
abs/10.1089/107999000414826
[35] Vermeire K, Heremans H, 
Vandeputte M, Huang S, Billiau A, 
Matthysz P. Accelerated collagen-
induced arthritis in IFN-y receptor-
deficient mice. Journal of Immunology. 
1997 Jun 1;158(11):5507-5513
[36] Wang Q, Rozelle AL, Lepus CM, 
Scanzello CR, Song JJ, Larsen M, et al. 
Identification of a central role for 
complement in osteoarthritis. Nature 
Medicine. 2012;17(12):1674-1679
[37] Ishii H, Tanaka H, Katoh K, 
Nakamura H, Nagashima M, Yoshino 
S. Characterization of infiltrating 
T cells and Th1/Th2-type cytokines 
in the synovium of patients with 
osteoarthritis. Osteoarthritis and 
Cartilage. 2002;10(4):277-281
[38] Sakkas LI, Scanzello C, Johanson N, 
Burkholder J, Mitra A, Salgame P, et al. 
T cells and T-cell cytokine transcripts 
in the synovial membrane in patients 
with osteoarthritis. Clinical and 
Diagnostic Laboratory Immunology. 
1998;5(4):430-437
[39] Kapoor M, Martel-Pelletier J, 
Lajeunesse D, Pelletier JP, Fahmi H. Role 
of proinflammatory cytokines in the 
pathophysiology of osteoarthritis. 
Nature Reviews Rheumatology. 
2011;7(1):33-42
[40] Saklatvala J. Tumour necrosis 
factor α stimulates resorption and 
inhibits synthesis of proteoglycan 
in cartilage. Nature. 1986 Aug 
7-13;322(6079):547-549
[41] Chadjichristos C, Ghayor C, 
Kypriotou M, Martin G, Renard E, Ala-
Kokko L, et al. Sp1 and Sp3 transcription 
factors mediate interleukin-1β 
down-regulation of human type II 
collagen gene expression in articular 
chondrocytes. The Journal of Biological 
Chemistry. 2003;278(41):39762-39772
Osteoarthritis Biomarkers and Treatments
12
[42] Shlopov BV, Gumanovskaya ML, 
Hasty KA. Autocrine regulation of 
collagenase 3 (matrix metalloproteinase 
13) during osteoarthritis. Arthritis and 
Rheumatism. 2000;43(1):195-205
[43] Fan Z, Bau B, Yang H, Soeder S, 
Aigner T. Freshly isolated osteoarthritic 
chondrocytes are catabolically more 
active than normal chondrocytes, but 
less responsive to catabolic stimulation 
with interleukin-1? Arthritis and 
Rheumatism. 2005;52(1):136-143
[44] Cortial D, Gouttenoire J, Rousseau 
CF, Ronzière MC, Piccardi N, Msika 
P, et al. Activation by IL-1 of bovine 
articular chondrocytes in culture 
within a 3D collagen-based scaffold. An 
in vitro model to address the effect of 
compounds with therapeutic potential 
in osteoarthritis. Osteoarthritis and 
Cartilage. 2006;14(7):631-640
[45] Silvestri T, Pulsatelli L, Dolzani P, 
Frizziero L, Facchini A, Meliconi R. 
In vivo expression of inflammatory 
cytokine receptors in the joint 
compartments of patients with 
arthritis. Rheumatology International. 
2006;26(4):360-368
[46] Roman-Blas JA, Jimenez SA. NF-κB 
as a potential therapeutic target 
in osteoarthritis and rheumatoid 
arthritis. Osteoarthritis and Cartilage. 
2006;14(9):839-848
[47] Kobayashi T, Notoya K, Naito T, 
Unno S, Nakamura A, Martel-Pelletier 
J, et al. Pioglitazone, a peroxisome 
proliferator-activated receptor γ 
agonist, reduces the progression of 
experimental osteoarthritis in Guinea 
pigs. Arthritis and Rheumatism. 
2005;52(2):479-487
[48] Boileau C, Martel-Pelletier J, Fahmi 
H, Mineau F, Boily M, Pelletier JP. The 
peroxisome proliferator-activated 
receptor γ agonist pioglitazone 
reduces the development of cartilage 
lesions in an experimental dog model 
of osteoarthritis: In vivo protective 
effects mediated through the inhibition 
of key signaling and catabolic 
pathways. Arthritis and Rheumatism. 
2007;56(7):2288-2298
[49] Wang P, Zhu F, Konstantopoulos 
K. Prostaglandin E 2 induces 
interleukin-6 expression in human 
chondrocytes via cAMP/protein kinase 
A- and phosphatidylinositol 3-kinase-
dependent NF-κB activation. American 
Journal of Physiology. Cell Physiology. 
2010;298:1445-1456
[50] Stannus O, Jones G, Cicuttini F, 
Parameswaran V, Quinn S, Burgess 
J, et al. Circulating levels of IL-6 
and TNF-α are associated with 
knee radiographic osteoarthritis 
and knee cartilage loss in older 
adults. Osteoarthritis and Cartilage. 
2010;18(11):1441-1447
[51] Sui Y, Lee JH, DiMicco MA, 
Vanderploeg EJ, Blake SM, Hung HH, 
et al. Mechanical injury potentiates 
proteoglycan catabolism induced by 
interleukin-6 with soluble interleukin-6 
receptor and tumor necrosis factor α 
in immature bovine and adult human 
articular cartilage. Arthritis and 
Rheumatism. 2009;60(10):2985-2996
[52] Rowan AD, Koshy PJT, Shingleton 
WD, Degnan BA, Heath JK, Vernallis 
AB, et al. Synergistic effects of 
glycoprotein 130 binding cytokines 
in combination with interleukin-1 on 
cartilage collagen breakdown. Arthritis 
and Rheumatism. 2001;44(7):1620-1632
[53] de Hooge ASK, van de Loo FAJ, 
Bennink MB, Arntz OJ, de Hooge P, van 
den Berg WB. Male IL-6 gene knockout 
mice developed more advanced 
osteoarthritis upon aging. Osteoarthritis 
and Cartilage. 2005;13(1):66-73
[54] van de Loo FA, Kuiper S, van 
Enckevort FH, Arntz OJ, van den Berg 
WB. Interleukin-6 reduces cartilage 
destruction during experimental 
13
Osteoarthritis as a Chronic Inflammatory Disease: A Review of the Inflammatory Markers
DOI: http://dx.doi.org/10.5772/intechopen.82565
arthritis. A study in interleukin-6-
deficient mice. The American Journal of 
Pathology. 1997;151(1):177-191
[55] Steeve KT, Marc P, Sandrine T, 
Dominique H, Yannick F. IL-6, RANKL, 
TNF-alpha/IL-1: Interrelations in 
bone resorption pathophysiology. 
Cytokine & Growth Factor Reviews. 
2004;15(1):49-60
[56] Massicotte F, Lajeunesse D, 
Benderdour M, Pelletier JP, Hilal G, 
Duval N, et al. Can altered production 
of interleukin-1β, interleukin-6, 
transforming growth factor-β and 
prostaglandin E2 by isolated human 
subchondral osteoblasts identity 
two subgroups of osteoarthritic 
patients. Osteoarthritis and Cartilage. 
2002;10(6):491-500
[57] Sakao K, Takahashi KA, Arai Y, 
Saito M, Honjo K, Hiraoka N, et al. 
Osteoblasts derived from osteophytes 
produce interleukin-6, interleukin-8, 
and matrix metalloproteinase-13 in 
osteoarthritis. Journal of Bone 
and Mineral Metabolism. 
2009;27(4):412-423
[58] Baslund B, Tvede N, Danneskiold-
Samsoe B, Larsson P, Panayi G, Petersen 
J, et al. Targeting interleukin-15 in 
patients with rheumatoid arthritis: A 
proof-of-concept study. Arthritis and 
Rheumatism. 2005;52(9):2686-2692
[59] Waldmann TA, Tagaya Y. 
The multifaceted regulation of 
Interleukin-15 expression and the 
role of this cytokine in Nk cell 
differentiation and host response to 
intracellular pathogens. Annual Review 
of Immunology. 1999;17(1):19-49
[60] Scanzello CR, Goldring SR. The 
role of synovitis in osteoarthritis 
pathogenesis. Bone. 2013;51(2):249-257
[61] Sun J-M, Sun L-Z, Liu J, Su B, 
Shi L. Serum Interleukin-15 levels 
are associated with severity of pain 
in patients with knee osteoarthritis. 
Disease Markers. 2013;35(3):203-206
[62] Wojdasiewicz P, Poniatowski 
ŁA, Szukiewicz D. The role of 
inflammatory and anti-inflammatory 
cytokines in the pathogenesis 
of osteoarthritis. Mediators of 
Inflammation. 2014;2014:561459
[63] Noordenbos T, Yeremenko N, Gofita 
I, Van De Sande M, Tak PP, Caňete JD, 
et al. Interleukin-17-positive mast cells 
contribute to synovial inflammation 
in spondylarthritis. Arthritis and 
Rheumatism. 2012;64(1):99-109
[64] Honorati MC, Neri S, Cattini L, 
Facchini A. Interleukin-17, a regulator 
of angiogenic factor release by synovial 
fibroblasts. Osteoarthritis and Cartilage. 
2006;14(4):345-352
[65] Lubberts E, Joosten LAB, Van De 
Loo FAJ, Van Den Bersselaar LAM, Van 
Den Berg WB. Reduction of interleukin-
17-induced inhibition of chondrocyte 
proteoglycan synthesis in intact murine 
articular cartilage by interleukin-4. 
Arthritis and Rheumatism. 
2000;43(6):1300-1306
[66] Chen B, Deng Y, Tan Y, Qin 
J, Bin CL. Association between 
severity of knee osteoarthritis and 
serum and synovial fluid interleukin 
17 concentrations. The Journal of 
International Medical Research. 
2014;42(1):138-144
[67] Han L, Lee HS, Yoon JH, Choi WS, 
Park YG, Nam SW, et al. Association 
of IL-17A and IL-17F single nucleotide 
polymorphisms with susceptibility to 
osteoarthritis in a Korean population. 
Gene. 2014;533(1):119-122
[68] Honorati MC, Cattini L, Facchini 
A. VEGF production by osteoarthritic 
chondrocytes cultured in micromass 
and stimulated by IL-17 and TNF-
α. Connective Tissue Research. 
2007;48(5):239-245
Osteoarthritis Biomarkers and Treatments
14
[69] Olee T, Hashimoto S, Quach 
J, Lotz M. IL-18 is produced by 
articular chondrocytes and induces 
proinflammatory and catabolic 
responses. Journal of Immunology. 
1999;162(2):1096-1100
[70] Dai SM, Shan ZZ, Nishioka K, 
Yudoh K. Implication of interleukin 
18 in production of matrix 
metalloproteinases in articular 
chondrocytes in arthritis: Direct effect 
on chondrocytes may not be pivotal. 
Annals of the Rheumatic Diseases. 
2005;64(5):735-742
[71] Joosten LAB, Smeets RL, Koenders 
MI, Van Den Bersselaar LAM, 
Helsen MMA, Oppers-Walgreen B, 
et al. Interleukin-18 promotes joint 
inflammation and induces interleukin-
1-driven cartilage destruction. The 
American Journal of Pathology. 
2004;165(3):959-967
[72] John T, Kohl B, Mobasheri a 
EW, Shakibaei M. Interleukin-18 
induces apoptosis in human articular 
chondrocytes. Histology  
and Histopathology. 
2007;22(5):469-482
[73] Wang Y, Xu D, Long L, Deng 
X, Tao R, Huang G. Correlation 
between plasma, synovial fluid and 
articular cartilage Interleukin-18 with 
radiographic severity in 33 patients 
with osteoarthritis of the knee. 
Clinical and Experimental Medicine. 
2014;14(3):297-304
[74] Hulin-Curtis SL, Bidwell JL, Perry 
MJ. Evaluation of IL18 and IL18R1 
polymorphisms: Genetic susceptibility 
to knee osteoarthritis. International 
Journal of Immunogenetics. 
2012;39(2):106-109
[75] Omair A. An association study 
of interleukin 18 receptor genes 
(IL18R1 and IL18RAP) in lumbar disc 
degeneration. Open Orthopaedics 
Journal. 2012;6(1):164-171
[76] Van Lent PLEM, Holthuysen 
AEM, Slöetjes A, Lubberts E, Van Den 
Berg WB. Local overexpression of 
adenoviral IL-4 protects cartilage from 
metalloproteinase-induced destruction 
during immune complex-mediated 
arthritis by preventing activation of 
pro-MMPs. Osteoarthritis and Cartilage. 
2002;10(3):234-243
[77] Millward-Sadler SJ, Wright MO,  
Davies LW, Nuki G, Salter 
DM. Mechanotransduction via 
integrins and interleukin-4 results 
in altered aggrecan and matrix 
metalloproteinase 3 gene expression in 
normal, but not osteoarthritic, human 
articular chondrocytes. Arthritis and 
Rheumatism. 2000;43(9):2091-2099
[78] Vargiolu M, Silvestri T, Bonora E, 
Dolzani P, Pulsatelli L, Addimanda 
O, et al. Interleukin-4/interleukin-4 
receptor gene polymorphisms in hand 
osteoarthritis. Osteoarthritis and 
Cartilage. 2010;18(6):810-816
[79] Yigit S, Inanir A, Tekcan A, Tural E, 
Ozturk GT, Kismali G, et al. Significant 
association of interleukin-4 gene 
intron 3 VNTR polymorphism with 
susceptibility to knee osteoarthritis. 
Gene. 2014;537(1):6-9
[80] Silvestri T, Pulsatelli L, Dolzani P, 
Facchini A, Meliconi R. Elevated serum 
levels of soluble interleukin-4 receptor 
in osteoarthritis. Osteoarthritis and 
Cartilage. 2006;14(7):717-719
[81] Bhattacharjee A, Shukla M, 
Yakubenko VP, Mulya A, Kundu S, 
Cathcart MK. IL-4 and IL-13 employ 
discrete signaling pathways for target 
gene expression in alternatively 
activated monocytes/macrophages. 
Free Radical Biology & Medicine. 
2013;54(216):1-16
[82] Van Meegeren MER, Roosendaal 
G, Jansen NWD, Wenting MJG, Van 
Wesel ACW, Van Roon JAG, et al. IL-4 
alone and in combination with IL-10 
15
Osteoarthritis as a Chronic Inflammatory Disease: A Review of the Inflammatory Markers
DOI: http://dx.doi.org/10.5772/intechopen.82565
protects against blood-induced cartilage 
damage. Osteoarthritis and Cartilage. 
2012;20(7):764-772
[83] Schuerwegh AJ, Dombrecht 
EJ, Stevens WJ, Van Offel JF, Bridts 
CH, De Clerck LS. Influence of pro-
inflammatory (IL-1α, IL-6, TNF-α, 
IFN-γ) and anti-inflammatory 
(IL-4) cytokines on chondrocyte 
function. Osteoarthritis and Cartilage. 
2003;11(9):681-687
[84] Yorimitsu M, Nishida K, Shimizu A, 
Doi H, Miyazawa S, Komiyama T, et al. 
Intra-articular injection of interleukin-4 
decreases nitric oxide production 
by chondrocytes and ameliorates 
subsequent destruction of cartilage in 
instability-induced osteoarthritis in rat 
knee joints. Osteoarthritis and Cartilage. 
2008;16(7):764-771
[85] Lacraz S, Nicod LP, Chicheportiche 
R, Welgus HG, Dayer JM. IL-10 
inhibits metalloproteinase and 
stimulates TIMP-1 production in 
human mononuclear phagocytes. 
The Journal of Clinical Investigation. 
1995;96(5):2304-2310
[86] Wang Y, Lou S. Direct protective 
effect of interleukin-10 on articular 
chondrocytes in vitro. Chinese Medical 
Journal. 2001;114(7):723-725
[87] John T, Müller RD, Oberholzer 
A, Zreiqat H, Kohl B, Ertel W, et al. 
Interleukin-10 modulates pro-apoptotic 
effects of TNF-α in human articular 
chondrocytes in vitro. Cytokine. 
2007;40(3):226-234
[88] Umulis D, O’Connor MB, 
Blair SS. The extracellular 
regulation of bone morphogenetic 
protein signaling. Development. 
2009;136(22):3715-3728
[89] Zeng L, Kempf H, Murtaugh LC, 
Sato ME, Lassar AB. Shh establishes an 
Nkx3.2/Sox9 autoregulatory loop that 
is maintained by BMP signals to induce 
somitic chondrogenesis. Genes & 
Development. 2002;16(15):1990-2005
[90] Alaaeddine N, Di Battista JA, 
Pelletier JP, Kiansa K, Cloutier JM, 
Martel-Pelletier J. Inhibition of 
tumor necrosis factor alpha-induced 
prostaglandin E2 production by 
the anti-inflammatory cytokines 
interleukin-4, interleukin- 10, and 
interleukin-13 in osteoarthritic synovial 
fibroblasts: Distinct targeting in the 
signaling pathways. Arthritis and 
Rheumatism. 1999;42(4):710-718
[91] Helmark IC, Mikkelsen UR, 
Børglum J, Rothe A, Petersen 
MC, Andersen O, et al. Exercise 
increases interleukin-10 levels both 
intraarticularly and peri-synovially 
in patients with knee osteoarthritis: A 
randomized controlled trial. Arthritis 
Research & Therapy. 2010;12(4):R126
[92] Angele P, Yoo JU, Smith C, 
Mansour J, Jepsen KJ, Nerlich M, 
et al. Cyclic hydrostatic pressure 
enhances the chondrogenic phenotype 
of human mesenchymal progenitor 
cells differentiated in vitro. 
Journal of Orthopaedic Research. 
2003;21(3):451-457
[93] Borzí RM, Mazzetti I, Cattini L, 
Uguccioni M, Baggiolini M, Facchini 
A. Human chondrocytes express 
functional chemokine receptors and 
release matrix-degrading enzymes 
in response to C-X-C and C-C 
chemokines. Arthritis and Rheumatism. 
2000;43(8):1734-1741
[94] Miller RJ, Banisadr G, 
Bhattacharyya BJ. CXCR4 signaling 




[95] Zou Y, Li Y, Lu L, Lin Y, Liang W, 
Su Z, et al. Correlation of fractalkine 
concentrations in serum and synovial 
fluid with the radiographic severity of 
Osteoarthritis Biomarkers and Treatments
16
knee osteoarthritis. Annals of Clinical 
Biochemistry. 2013;50(6):571-575
[96] Kanda H, Tateya S, Tamori Y, Kotani 
K, Hiasa K, Kitazawa R, et al. MCP-1 
contributes to macrophage infiltration 
into adipose tissue, insulin resistance, 
and hepatic steatosis in obesity. The 
Journal of Clinical Investigation. 
2006;116(6):1494-1505
[97] Li L, Jiang BE. Serum and 
synovial fluid chemokine ligand 2/
monocyte chemoattractant protein 
1 concentrations correlates with 
symptomatic severity in patients with 
knee osteoarthritis. Annals of Clinical 
Biochemistry. 2015;52(2):276-282
[98] Beekhuizen M, Gierman LM, van 
Spil WE, Van Osch GJVM, Huizinga 
TWJ, Saris DBF, et al. An explorative 
study comparing levels of soluble 
mediators in control and osteoarthritic 
synovial fluid. Osteoarthritis and 
Cartilage. 2013;21(7):918-922
[99] Conde J, Scotece M, Gómez R, 
Lopez V, Gómez-Reino JJ, Gualillo O. 
Adipokines and osteoarthritis: Novel 
molecules involved in the pathogenesis 
and progression of disease. Arthritis. 
2011;2011:1-8
[100] Clockaerts S, Bastiaansen-
Jenniskens YM, Runhaar J, Van 
Osch GJVM, Van Offel JF, Verhaar 
JAN, et al. The infrapatellar fat pad 
should be considered as an active 
osteoarthritic joint tissue: A narrative 
review. Osteoarthritis and Cartilage. 
2010;18(7):876-882
[101] Geng Y, Blanco FJ, Cornelisson M, 
Lotz M. Regulation of cyclooxygenase-2 
expression in normal human articular 
chondrocytes. Journal of Immunology. 
1995;155(2):796-801
[102] Martel-Pelletier J, Pelletier JP, 
Fahmi H. Cyclooxygenase-2 and 
prostaglandins in articular tissues. 
Seminars in Arthritis and Rheumatism. 
2003;33(3):155-167
[103] Oliveira SHP, Canetti C, Ribeiro 
RA, Cunha FQ. Neutrophil migration 
induced by IL-1β depends upon LTB4 
released by macrophages and upon 
TNF-α and IL-1β released by mast cells. 
Inflammation. 2008;31(1):36-46
